Hilarious, absolutely hilarious!
Wednesday February 21, 1:56 pm Eastern Time
Press Release
SOURCE: BioPulse International, Inc.
BioPulse Addresses Letter to
Shareholders
SAN DIEGO, Feb. 21 /PRNewswire/ -- BioPulse International, Inc., (OTC Bulletin Board:
BIOP; Frankfurt: BPZ) today addressed a letter to its shareholders. The text of the letter follows.
In another release, the company announced because of Dr. Reid Jilek's business travel in Europe
today's conference call will occur at a later date. In recent weeks, there has been media coverage
of BioPulse focusing on the clinic of Dr. Sanchez in Tijuana, Mexico. Some of the coverage has
been positive and some negative. Most recently, the coverage has focused on the clinic's licenses
and its relationship with the Mexican Health Department. We are assured that the clinic is
cooperating with the Health Department to get all of its permits in order.
We understand that our shareholders are interested and concerned about these developments,
and we will endeavor to give you updates as we receive them. However, this focus on the clinics
has detracted from the overall business objectives of BioPulse.
Our ultimate objective at BioPulse is to provide a better way to deal with the scourge of cancer.
We believe early detection and careful monitoring of cancer patients undergoing treatment will
save many lives and, as importantly, improve the quality of life of cancer patients. We also believe
that host non-toxic treatments will become increasingly accepted even in the mainstream U.S.
medical system.
We have licensed the rights to some cancer diagnostic and therapeutic technology that we believe
can make a difference in the fight against cancer. We believe the TK1 test that we are developing
will provide a useful screening test that will help save lives. We also believe the TK1 test will aid
oncologists in monitoring a patient's response to treatment. And we believe the TK1 test will help
clinicians predict recurrence, making it possible to customize treatments more effectively.
While this work is still in the development stage, we believe we are making good progress and
will be able to offer, first to researchers and then to medical practitioners, an important new tool
in the fight against cancer.
We are also studying various cancer treatments that we licensed from Aidan, Inc., as explained
on our web page.
In the meantime, despite the attacks of our critics, we have no debt, we have cash in the bank,
and we have ongoing revenues. We believe we will be able to continue the development of our
technology and continue to expand our revenue and profitability.
We appreciate your support as we work through this difficult period. We invite your comments
and questions, and we will attempt to respond to these in future letters to the shareholders.
The Board of Directors
Various statements made within this letter may constitute ``forward-looking statements'' for
purposes of the Securities and Exchange Commission's ``safe harbor'' provisions under the
Private Securities Litigation Reform Act of 1995 and Rule 3b-6 under the Securities Exchange
Act of 1934. The forward-looking statements contained herein involve risks and uncertainties that
could cause results to differ materially from the Company's expectations.
CONTACT: Loran Swensen of BioPulse International, Inc., 619-572-8839.
SOURCE: BioPulse International, Inc. |
